11.48
price down icon0.86%   -0.10
after-market Handel nachbörslich: 11.48
loading
Schlusskurs vom Vortag:
$11.58
Offen:
$11.67
24-Stunden-Volumen:
8.77M
Relative Volume:
1.41
Marktkapitalisierung:
$7.86B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
2.0319
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+4.27%
1M Leistung:
+13.89%
6M Leistung:
-1.71%
1J Leistung:
+2.14%
1-Tages-Spanne:
Value
$11.46
$11.73
1-Wochen-Bereich:
Value
$11.01
$11.77
52-Wochen-Spanne:
Value
$8.73
$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name
Firmenname
Roivant Sciences Ltd
Name
Telefon
441-295-5950
Name
Adresse
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Name
Mitarbeiter
908
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
ROIV's Discussions on Twitter

Vergleichen Sie ROIV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ROIV
Roivant Sciences Ltd
11.48 7.86B 125.68M 4.81B -781.21M 5.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-15 Eingeleitet Wolfe Research Outperform
2024-01-05 Eingeleitet Piper Sandler Overweight
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-17 Eingeleitet Guggenheim Buy
2023-06-08 Eingeleitet BofA Securities Neutral
2022-10-27 Eingeleitet JP Morgan Overweight
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-04-29 Eingeleitet Cantor Fitzgerald Overweight
2021-12-15 Eingeleitet Goldman Buy
2021-11-08 Eingeleitet H.C. Wainwright Buy
2021-10-28 Eingeleitet Citigroup Buy
2021-10-26 Eingeleitet Cowen Outperform
2021-10-26 Eingeleitet Jefferies Buy
2021-10-26 Eingeleitet Truist Buy
Alle ansehen

Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten

pulisher
10:37 AM

Roivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside Potential - Yahoo Finance

10:37 AM
pulisher
Apr 29, 2025

Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey

Apr 29, 2025
pulisher
Apr 24, 2025

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update - ADVFN

Apr 24, 2025
pulisher
Apr 23, 2025

Roivant Sciences: Primed For Growth With A De-Risked Pipeline (NASDAQ:ROIV) - Seeking Alpha

Apr 23, 2025
pulisher
Apr 22, 2025

Roivant sciences president Eric Venker sells $1.02 million in stock By Investing.com - Investing.com India

Apr 22, 2025
pulisher
Apr 22, 2025

Roivant sciences president Eric Venker sells $1.02 million in stock - Investing.com

Apr 22, 2025
pulisher
Apr 22, 2025

Roivant Sciences stock holds $18 target, management shuffle - Investing.com Australia

Apr 22, 2025
pulisher
Apr 22, 2025

Roivant Sciences stock holds $18 target, management shuffle By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 21, 2025

Cantor Fitzgerald maintains overweight on Roivant Sciences stock - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Immunovant makes leadership changes - MSN

Apr 21, 2025
pulisher
Apr 21, 2025

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com

Apr 21, 2025
pulisher
Apr 21, 2025

Cantor Fitzgerald maintains overweight on Roivant Sciences stock By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 21, 2025

Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - marketscreener.com

Apr 21, 2025
pulisher
Apr 18, 2025

When (ROIV) Moves Investors should Listen - news.stocktradersdaily.com

Apr 18, 2025
pulisher
Apr 11, 2025

Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In - Insider Monkey

Apr 10, 2025
pulisher
Apr 09, 2025

ROIV Factor-Based Stock Analysis - Nasdaq

Apr 09, 2025
pulisher
Apr 07, 2025

Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN

Apr 07, 2025
pulisher
Apr 02, 2025

Knott David M Jr Decreases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

KLP Kapitalforvaltning AS Invests $918,000 in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Apr 02, 2025
pulisher
Mar 31, 2025

ROIV stock touches 52-week low at $9.96 amid market fluctuations By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com Australia

Mar 31, 2025
pulisher
Mar 29, 2025

Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat

Mar 28, 2025
pulisher
Mar 25, 2025

Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey

Mar 25, 2025
pulisher
Mar 24, 2025

Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com

Mar 24, 2025
pulisher
Mar 23, 2025

(ROIV) Trading Advice - news.stocktradersdaily.com

Mar 23, 2025
pulisher
Mar 20, 2025

Roivant Sciences finalizes consulting agreement with former officer - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com

Mar 19, 2025
pulisher
Mar 19, 2025

Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks

Mar 19, 2025
pulisher
Mar 18, 2025

Critical Clinical Data Coming: Roivant's Dual Breakthrough Results in MG and CIDP Studies - Stock Titan

Mar 18, 2025
pulisher
Mar 12, 2025

(ROIV) Trading Signals - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 12, 2025

Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to Trade - Nasdaq

Mar 12, 2025
pulisher
Mar 11, 2025

Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 07, 2025

Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey

Mar 07, 2025
pulisher
Mar 04, 2025

Genevant and Arbutus initiate patent lawsuit against Moderna - The Pharma Letter

Mar 04, 2025
pulisher
Mar 04, 2025

10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey

Mar 04, 2025
pulisher
Mar 03, 2025

Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey

Mar 03, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Mar 03, 2025
pulisher
Mar 02, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World

Mar 02, 2025

Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Venker Eric
President & COO
Apr 21 '25
Sale
10.22
100,000
1,022,000
1,116,345
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):